Hepatic Comorbidity & Coinfections

Module 16, Version 4

References

  • Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:e1-e34.
  • Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B infection. J Hepatol. 2018 Apr; 68(4):672-681.
  • Alter MJ. Epidemiology of viral hepatitis and HIV coinfection. J Hepatol. 2006;44(1Suppl):S6-S9.
  • Bevilacqua E, Fabris A, Floreano P, et al. Genetic factors in mother-to-child transmission of HCV infection. Virology. 2009;390:64-70.
  • Boerekamps A, Weggheleire AD, van den Berk G, et al. Treatment of acute hepatitis C genotypes 1 and 4 with 9 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4(4):269-277.
  • Braun D, Hampel BH, Ledergerber B, et al. A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study. Clin Infect Dis. 2020;ciaa1124. doi: 10.1093/cid/ciaa1124. Online ahead of print.
  • Braun D, Hampel BH, Martin E, et al. High number of potential transmitters revealed in a population-based systematic hepatitis C virus RNA screening among human immunodeficiency virus-infected men who have sex with men. Clin Infect Dis. 2019;68(4):561-568.
  • Cento V, Chevaliez S, Perno CF, et al. Resistance to direct-acting antiviral agents: clinical utility and significance. Curr Opin HIV AIDS. 2015;10(5):381-9.
  • Child C, Turcotte J. The liver and portal hypertension. In: Child CI, ed. Surgery and Portal Hypertension. Philadelphia, USA: W. B. Saunders, 1964:50-58.
  • Colin J, Cazals-Hatem D, Loriot M, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatol. 1999;29:1306-1310.
  • Dore G, Soriano V, Rockstroh J, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus coinfected patients following antiretroviral therapy interruption. AIDS. 2010;24:857-865.
  • El-Sadr WM, Lundgren JD, Neaton JD, et al., Smart-Study-Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-2296.
  • Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396-407.
  • European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
  • European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2020. J Hepatol. 2020;73:41170-1218.
  • Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020;71(2):686-721. http://www.hcvguidelines.org.
  • Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel. JAMA. 2014;312(4):410-425.
  • Hadziyannis S, Papatheodoridis G. Hepatitis B e antigen-negative chronic hepatitis B: Natural history and treatment. Semin Liver Dis. 2006;26:130-141.
  • Heuft M, Houba S, van den Berk G, et al. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS. 2014;28:999-1005.
  • Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797-805.
  • Kao JH. Molecular epidemiology of hepatitis B virus. Korean J Intern Med. 2011;26:255-261.
  • Kronfi N, Bhatnager SR, Hull MW, et al. Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C scale-up. AIDS. 2019;33(6):1013-1022.
  • Launay O, Van der Vliet D, Rosenberg A, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: A randomized controlled trial. JAMA. 2011;305:1432-1440.
  • Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436.
  • Linas BP, Wang B, Smurzynski M, et al. The impact of HIV/HCV coinfection on health care utilization and disability: Results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011;18:506-512.
  • Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology. 2009;50:661-662.
  • Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis c virus genotypes. Hepatology. 2015;61:77-87.
  • Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705-713.
  • Patel SV, Jayaweera DT, Althoff KN, et al. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. PLoS One. 2020;15(2):e0228847.
  • Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis. 1995;171:1607-1610.
  • Pinchoff J, Drobnik A, Bornschlegel K, et al. Deaths among people with hepatitis C in New York City, 2000-2011. Clin Infect Dis. 2014;58:1047-1054.
  • Poordad F, Dieterich D. Treating hepatitis C: Current standard of care and emerging direct-acting antiviral agents. J Viral Hepat. 2012;19:449-464.
  • Rockstroh J, Lacombe K, Viani R, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus-1: the Expedition-2 Study. Clin Infect Dis. 2018;67(7):1010-1017.
  • Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV coinfection (C-EDGE COINFECTION): A non-randomised, open-label trial. Lancet HIV. 2015;2:e319-e327.
  • Ruane PJ, DeJesus E Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-daymonotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63:449-455.
  • Saco TV, Strauss AT, Ledford DK. Hepatitis B vaccine non-responders: possible mechanisms and solutions. Ann Allergy Asthma Immunol. 2018 Sep;121(3):320-327.
  • Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase III, non-inferiority trials. Lancet. 2015;385:2606-2615.
  • Sherman K. Management of the hepatitis B virus/HIV-coinfected patient. Top Antivir Med. 2015;23:111-114.
  • Shire N, Rouster S, Rajicic N, et al. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;36:869-875.
  • Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment Web resource. Hepatology. 2014;59:318-327.
  • Splawn LM, Bailey CA, Medina JP, et al. Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States. Drugs Today (Barc). 2018;54(7):399-405.
  • Spradling PR, Richardson JT, Buchacz K, et al. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. J Acquir Immune Defic Syndr. 2010;53(3):388-96.
  • Sulkowski M, Thomas D, Chaisson R, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2001;32:144-148.
  • Surial B, Béguelin C, Chave J-P, et al. Switching from TDF to TAF in HIV/HBV co-infected individuals with renal dysfunction - a prospective cohort study. J Acquir Immune Defic Syndr. 2020 Jul 2;doi: 10.1097/QAI.0000000000002429. Online ahead of print.
  • Tedaldi E, Peters L, Neuhaus J, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis. 2008;47(11):1468-1475.
  • Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partner study. Hepatology. 2013;57:881-889
  • Terrault NA, Lok AS, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67:1560-1599.
  • Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.
  • Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss HIV Cohort Study: A rapidly evolving epidemic. Clin Infect Dis. 2012;55:1408-1416.
  • Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med. 2006;166:1632-1641.
  • Wyles D, Brau N, Kottilil S, et al. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type1: an open-label, phase 3 study. Clin Infect Dis. 2017;65(1):6-12.
  • Zahnd C, Salazar-Vizcaya L, Dufour JF, et al. Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men. J Hepatol. 2016;65:26-32.
  • Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology. 1996;24:1003-1009.
  • Agarwal K, Fung S, Seto WK, et al. A phase III study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg- positive, chronic hepatitis B (CHB): Efficacy and safety results at week 96. Program and abstracts of the 2017 European Association for the Study of the Liver annual meeting; April 19-23, 2017; Amsterdam, The Netherlands. Abstract FRI-153.
  • Boesecke C, Martinez EM, Nelson M, et al. PROBE-C Study: rate of spontaneous clearance of acute HCV in persons with HIV. CROI 2018. March 4-7, 2018. Boston, MA. Abstract 129.
  • Brunetto M, Lim YS, Gane E, et al. A phase III study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: Efficacy and safety results at week 96. Program and abstracts of the 2017 European Association for the Study of the Liver annual meeting; April 19-23, 2017; Amsterdam, The Netherlands. Abstract PS-042.

Thank you for visiting the AAHIVM Provider Education Center! 

In order to continue, we will need you to create a profile. This will help us keep track of your education activity and CME accreditations.

           NEW USERS CLICK HERE TO CREATE A PROFILE.           

ALREADY CREATED YOUR AAHIVM PROFILE? CLICK HERE TO SIGN IN.

Are you an AAHIVM member? If not, consider supporting the Academy and programs like these. Click here to become an Academy member.

 

Connect

Phone: 202-659-0699
Fax: 202-659-0976

Contact

AAHIVM National Office
1627 Eye St NW Suite 835
Washington, D.C. 20006

About

The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.